IL239736A0 - New pitfalls in the treatment of macular degeneration - Google Patents

New pitfalls in the treatment of macular degeneration

Info

Publication number
IL239736A0
IL239736A0 IL239736A IL23973615A IL239736A0 IL 239736 A0 IL239736 A0 IL 239736A0 IL 239736 A IL239736 A IL 239736A IL 23973615 A IL23973615 A IL 23973615A IL 239736 A0 IL239736 A0 IL 239736A0
Authority
IL
Israel
Prior art keywords
treatment
macular degeneration
traps
novel
novel traps
Prior art date
Application number
IL239736A
Other languages
English (en)
Hebrew (he)
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of IL239736A0 publication Critical patent/IL239736A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL239736A 2013-01-25 2015-07-01 New pitfalls in the treatment of macular degeneration IL239736A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756778P 2013-01-25 2013-01-25
PCT/US2014/012356 WO2014116593A1 (en) 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
IL239736A0 true IL239736A0 (en) 2015-08-31

Family

ID=51227964

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239736A IL239736A0 (en) 2013-01-25 2015-07-01 New pitfalls in the treatment of macular degeneration

Country Status (13)

Country Link
US (2) US10111862B2 (show.php)
EP (1) EP2948436A4 (show.php)
JP (1) JP6266023B2 (show.php)
KR (1) KR20150120380A (show.php)
CN (1) CN105228989A (show.php)
AU (1) AU2014209585A1 (show.php)
CA (1) CA2898869A1 (show.php)
HK (1) HK1217490A1 (show.php)
IL (1) IL239736A0 (show.php)
MX (1) MX2015009444A (show.php)
RU (1) RU2015126015A (show.php)
SG (1) SG11201505599YA (show.php)
WO (1) WO2014116593A1 (show.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
JP5885670B2 (ja) 2009-12-11 2016-03-15 アルデイラ セラピューティクス, インコーポレイテッド 黄斑変性の処置のための組成物および方法
CN105073714A (zh) 2012-12-20 2015-11-18 奥尔德拉医疗公司 迫位原醇
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス, インコーポレイテッド 毒性アルデヒド関連疾患および処置
JPWO2016021706A1 (ja) * 2014-08-08 2017-05-25 カズマパートナーズ株式会社 縮合複素環化合物
WO2017035077A1 (en) * 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CN116531400A (zh) 2016-02-28 2023-08-04 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス, インコーポレイテッド 眼科用製剤およびその使用
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US20220313722A1 (en) * 2019-09-09 2022-10-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
AU2020419515A1 (en) * 2019-12-30 2022-05-19 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5742954A (en) 1996-11-22 1998-04-28 Softub, Inc. Electrically powered spa jet unit
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
KR20010041811A (ko) 1998-03-12 2001-05-25 온토젠 코포레이션 단백질 티로신 포스파타제의 조절제
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2305308A1 (en) 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
CN100558360C (zh) 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
RU2006133300A (ru) 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
AU2005302608A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
PT1888548E (pt) * 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
NZ572591A (en) 2006-04-14 2012-01-12 Prana Biotechnology Ltd 3N-substituted 8-hydroxy-quinazolin-4-ones
WO2008014602A1 (en) 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Quinoline derivatives
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
AU2009282076A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
JP5885670B2 (ja) * 2009-12-11 2016-03-15 アルデイラ セラピューティクス, インコーポレイテッド 黄斑変性の処置のための組成物および方法
US9718796B2 (en) 2011-01-12 2017-08-01 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012105887A1 (en) 2011-01-31 2012-08-09 Tim Bowden Active principle for mitigating undesired medical conditions
CN105073714A (zh) 2012-12-20 2015-11-18 奥尔德拉医疗公司 迫位原醇
JP6514114B2 (ja) * 2013-01-23 2019-05-15 アルデイラ セラピューティクス, インコーポレイテッド 毒性アルデヒド関連疾患および処置

Also Published As

Publication number Publication date
EP2948436A1 (en) 2015-12-02
MX2015009444A (es) 2016-04-15
RU2015126015A (ru) 2017-03-03
US10111862B2 (en) 2018-10-30
US20190125729A1 (en) 2019-05-02
US20150344447A1 (en) 2015-12-03
HK1217490A1 (zh) 2017-01-13
JP2016505637A (ja) 2016-02-25
KR20150120380A (ko) 2015-10-27
JP6266023B2 (ja) 2018-01-24
WO2014116593A1 (en) 2014-07-31
EP2948436A4 (en) 2016-07-13
AU2014209585A1 (en) 2015-07-23
SG11201505599YA (en) 2015-08-28
CN105228989A (zh) 2016-01-06
CA2898869A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
IL239736A0 (en) New pitfalls in the treatment of macular degeneration
IL239836A0 (en) Treatment of age-related macular degeneration
IL286759A (en) Therapeutic methods and preparations
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
GB2521737B (en) Tobacco treatment
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
ZA201505390B (en) Compositions and methods for treating pests
GB2521738B (en) Tobacco material and treatment thereof
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
GB201420103D0 (en) Treating particles
GB201308244D0 (en) Soil treatment
PL2956020T3 (pl) Obróbka tytoniu
SG10201912901YA (en) Compositions and methods for treating and preventing macular degeneration
GB201419295D0 (en) Tobacco material and treatment thereof
IL247116B (en) Compositions and methods for treating and preventing macular degeneration
GB201304872D0 (en) Treatment
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
GB201307310D0 (en) Treatment
GB2514124B (en) Turf Treatment
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment
GB201511772D0 (en) Improvements in the treatment of ash
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201409978D0 (en) Novel compounds and their use in therapy